KAVINGALI, CORP.

Automated Process Solutions for Healthcare and Clinical Research

Kavingali is a healthcare technology company.  

  • Engage DMR™: an individual based digital medical record system that allows users to share and monetize de-identified health data.

  • ACRUS™: a Robotic Process Automated (RPA) coding and utilization review software

  • ERIC™ Electronic Research Intelligence Cloud - a force multiplier employing RPA and AI for clinical research. 

EXPERTS IN HEALTHCARE TECHNOLOGY

Business Meeting

WE DEVELOP ROBOTIC PROCESS AUTOMATION SOFTWARE

 

PRESS RELEASES

OCTOBER 2020

Kavingali, Corp. Debuts Innovative Automated Utilization Review Software

 

The company’s RPA-driven system, ACRUS ™ , addresses missed revenue in utilization review management by

unlocking the full potential of automation technologies.

 

October 13, 2020 - Casper, WY - Kavingali Corp., a medical technology company focused on the innovation and delivery of applications designed to transform current healthcare processes, announces its newest SaaS solution, Automated Cloud Revenue Utilization System (ACRUST​™).  Created by a team of physician advisors and software

experts, ACRUS is a proprietary robotic process automation (RPA) system that employs Blue Prism® , Amazon

Web Services (AWS) , and Microsoft Azure with its own proprietary database to completely automate the UR and

appeals process for healthcare systems.

ACRUS was developed to solve one of the healthcare industry’s major challenges: inefficiencies in the effective collection of revenue for patients who qualify for inpatient status which currently results in a significant loss of revenue. By leveraging the latest technology via digital robots (RPA), ACRUS empowers U.S. healthcare systems to maximize their revenue by enhancing the process of inpatient determination while realizing a 60 percent reduction in overhead in the UR and Appeals departments. The system accomplishes this by credentialing the digital bot(s) like a human worker. The bots are able to perform a number of tasks, such as medical coding an entire encounter in ICD-10 as well as identifying billing conflicts to alert the billing department.

   

ACRUS’ innovative functionality affords healthcare systems a number of benefits:

●  Accuracy - Achieves at least a 10 percent increase in accuracy - not possible with human skill sets

●  Efficiency - Five digital bots complete over 43,000 manual review hours per year

●  Interoperability - Accesses all current and legacy EHR systems and commercial payer systems organically

●  Reliability - Operates 24/7/365

●  Safety - Monitors for potential patient risk and alerts risk management personnel

●  Seamlessness - Requires no human process beyond quality control

 

“ACRUS is the most disruptive technology for the healthcare utilization review processes in the last 30 years,” said Dr. Leigh J Mack, CEO of Kavingali. “We project that a typical 1,000 bed hospital can save approximately 40 percent in net overhead and realize at least 10 percent increase in efficiency and accuracy in inpatient status placement - translating to approximately $30 million in additional revenue.”

ACRUS will be available in January of 2021 to healthcare systems of all sizes interested in reducing expenses and improving efficiencies in their utilization and appeals departments.

About Kavingali, Corp.

Kavingali is a Veteran-owned medical technology company headquartered in Casper, Wyoming that specializes in

cutting-edge software solutions which automate and address process deficiencies while enhancing revenue

opportunities. Their solutions are created to transform healthcare with automation while enhancing patient care.

Kavingali remains dedicated to their vision of transforming the way healthcare technology improves processes

and delivers value from both revenue and cost savings perspectives.

Contact

Public Relations

pr@kavingali.com

JULY 2022

Kavingali announces Engage DMR -- Independent Control and Monetization of Your Healthcare Data

 

FOR IMMEDIATE RELEASE

July 22, 2022

Casper, Wyoming -- Kavingali, Corp. announces the launch of a brand new, secure platform called Engage DMR™ that will democratize payment for personal health data.  It will allow users (patient/healthcare consumer) to control access to their personal medical records and provide the opportunity to sell their de-identified data in a secure marketplace. Engage DMR (digital medical record) uniquely offers, secure medical record storage that permits the user to share and directly sell their de-identified data.  De-identified data is data that has been stripped of all personal information that could be traced back to an individual. 

Engage DMR works easily via downloading an app that will collect your medical records and de-identify them (so no one knows it is your data), then you opt in and get paid in a fairly short period of time. The platform is user (patient/healthcare consumer) centric and offers the opportunity for users to control and monetize their own medical data.  The platform will democratize the current revenue model of healthcare providers and other companies who sell data to pharmaceutical companies, commercial insurers, and others by switching the control over to the individual users.

Such de-identified data typically also includes real world evidence (RWE) and patient reported outcomes (PRO).  This user reported data that gets collected along with the de-identified data from medical records when combined have a rough market value between $1,000 and $18,000 annually.  This depends on medical conditions, per patient, per company that is buying the data.  Large pharmaceutical companies are now paying tens of millions of dollars for de-identified data.

The marketplace for de-identified data has greatly expanded in the past decade, to include the U.S. Federal Drug Administration (FDA) placing additional focus on RWE and PRO with the 21st Century Cures Act, passed in 2016.  In addition, pharmaceutical companies along with medical device companies have found that this data offers key insights into how effectively a drug or device works after it has been released to the market.  As a result, such new access to mass data may also offer new insights into dosages and the efficacy of current treatments at a much faster and efficient pace.  The market demand for this data is growing, but most private individuals never see a dime from any of these transactions that utilizes their own personal data.

The technology has already performed well in the HHS/FDA regulated space. Engage DMR is designed to collect and store full gene sequences, traditional medical histories, images, lab data and direct data collected from the user’s wearable devices.  Interoperability has been accomplished by a proprietary method to easily migrate any EHR data easily into the platform.  Additionally, Engage DMR users will have an opportunity to opt in to be considered for clinical trials, in which they meet the inclusion and exclusion criteria.  Fitness, medical and wellness devices can easily be linked allowing users to opt in and share ongoing medical data with a pharmaceutical, medical device or insurance companies.

 

Kavingali, Corp. will disrupt the healthcare data industry by being the first to split revenues with individual patients.  They will do so by providing a HIPAA compliant, secure platform that employs blockchain technology along with robotic process automation and microservices with users that allows the retention of 50% of the revenue.  User payments will be paid via electronic payment and users can additionally opt in to have deposits made to health savings accounts.  Kavingali, Corp. estimates that users, depending on medical conditions and data shared, could expect between $1,000 and $4,000 per year in payments.

Dr. Leigh Mack the CEO of Kavingali, Corp. had this to say about it, “This is one of the most disruptive healthcare technology innovations in the last 50 years.  This will allow the masses to take personal control over their medical records.”

 

 For more details about Engage DMR email pr@kavingali.com